Mast Cell Activation Syndrome (MCAS): Diagnosis, Treatment, Triggers, and the MCAS-POTS-EDS Connection

Mast cell activation syndrome (MCAS) is a chronic immune disorder in which normal-count mast cells release histamine, tryptase, prostaglandins and other chemical mediators too easily, causing episodic symptoms in two or more organ systems, such as flushing, hives, abdominal cramps, wheezing, brain fog and a racing heart. An international consensus led by Valent et al. (2012) diagnoses MCAS when three things are present together: typical symptoms, a measured rise in mast cell mediators during a flare, and a clear response to mast cell-directed treatment.

If you've been told your symptoms "don't make sense," that you can't possibly have hives, brain fog, nausea, a racing heart and throat tightness all from the same condition, you should know that you can. There is a name for it. Mast cell activation syndrome is one of the most under-recognized and misunderstood conditions in medicine, partly because it affects so many organ systems at once that no single specialist sees the full picture.

Many MCAS patients see several specialists before anyone names the pattern. Many are told it's anxiety, or that their labs are "normal" so nothing is wrong. This guide gives you and your providers a clear picture of what MCAS is, how it is diagnosed, which treatments have the most support, and how MCAS connects to other conditions you may already be dealing with.

What Is MCAS?

MCAS stands for mast cell activation syndrome. It is a mast cell disorder in which mast cells of normal number and appearance release their chemical mediators in response to triggers that should be harmless, such as heat, foods, fragrances, stress or friction. The result is episodic, multi-system symptoms that come and go in flares.

MCAS is distinct from classic allergy. In an IgE allergy, a specific allergen triggers a predictable reaction; in MCAS, reactions often have no single allergen, shift over time and involve the gut, skin, lungs, heart and nervous system at once. Allergist/immunologists diagnose most cases, with hematologists involved when systemic mastocytosis needs to be ruled out.

What does MCAD mean in mast cell disease?

MCAD stands for mast cell activation disease, an umbrella term used by Molderings and colleagues for the whole group of disorders driven by abnormal mast cell activity, including MCAS and systemic mastocytosis. Some clinicians also use "mast cell activation disorder" for the same idea. MCAD is easy to confuse with medium-chain acyl-CoA dehydrogenase deficiency, an unrelated inherited metabolic condition with the same abbreviation, so check which one a source means.

Is MCAS a recognized diagnosis?

Yes. MCAS is described in international consensus criteria (Valent et al., 2012; Afrin et al., 2021) and has its own ICD-10-CM diagnosis codes in the D89.4 group, which separate monoclonal, idiopathic and secondary mast cell activation. What remains debated is how strictly to apply the lab criteria, which is why two patients with similar symptoms can receive different answers from different specialists.

What Are Mast Cells and What Goes Wrong in MCAS?

Mast cells are sentinel immune cells that live in connective tissue throughout your body, concentrated in the skin, gut lining, respiratory tract, and around blood vessels and nerves. They're essentially the immune system's first responders, packed with 500 to 1,000 granules containing over 200 different chemical mediators, including histamine, prostaglandins, leukotrienes, cytokines and tryptase.

When functioning normally, mast cells do critical work: defending against pathogens, coordinating wound healing, mediating allergic responses and regulating blood vessel tone. The problem in MCAS isn't that you have too many mast cells (that's mastocytosis). It's that your normal-count mast cells are stuck in a hypervigilant state, degranulating (releasing their chemical contents) in response to stimuli that should be harmless.

The result is a cascade of chemical mediators flooding tissues throughout your body, causing inflammation, vasodilation, smooth muscle contraction, nerve irritation and immune dysregulation that can mimic dozens of different conditions at the same time.

MCAS Symptoms: The Multi-System Picture

MCAS symptoms are episodic reactions in two or more body systems at once, most often the skin (flushing, hives, itching), the gut (cramping, diarrhea, nausea), the airways (wheezing, throat tightness), the heart and circulation (tachycardia, lightheadedness) and the nervous system (brain fog, headaches, fatigue). The pattern across systems matters more than any single symptom.

The hallmark of MCAS is that symptoms are episodic and unpredictable. Patients describe good days and terrible days with no apparent rhyme or reason, until they learn to identify their personal triggers. Symptoms tend to wax and wane, and flares can last hours to weeks.

Which MCAS symptoms overlap with other conditions?

MCAS symptoms overlap heavily with irritable bowel syndrome, chronic urticaria, asthma, migraine, chronic fatigue syndrome and long COVID, which is a major reason diagnosis takes so long. Gut-dominant MCAS is often first labeled irritable bowel syndrome, and exhaustion with brain fog can look like chronic fatigue syndrome. When headaches lead the picture, the migraine condition guide and the national list of clinics offering migraine treatment are useful starting points, as long as the clinician also asks about flushing, hives and gut symptoms. A printable MCAS symptoms checklist helps you bring the full multi-system picture to an appointment.

Common MCAS Triggers

Triggers vary enormously between patients, which is one of the most frustrating aspects of MCAS. What devastates one person may not affect another at all. These are the most commonly reported categories:

• Foods: High-histamine foods (aged cheese, fermented foods, alcohol, processed meats such as salami, citrus, shellfish), leftover foods (histamine increases as food ages), and foods that trigger your individual mast cells. See our histamine intolerance guide for detailed food lists.
• Environmental: Heat and cold exposure, sun, changes in barometric pressure, fragrances and chemicals, cleaning products and, critically, mold.
• Physical: Exercise (especially intense or sustained), vibration, pressure on skin, friction and physical overexertion.
• Emotional: Stress (one of the most potent triggers), strong emotions, sleep deprivation and sympathetic nervous system activation.
• Hormonal: Menstrual cycle (estrogen promotes mast cell degranulation, and many patients flare premenstrually), perimenopause and other hormonal fluctuations.
• Medications: NSAIDs, opioids, muscle relaxants, certain antibiotics (vancomycin, fluoroquinolones), contrast dyes and some anesthetic agents.
• Infections: Viral, bacterial or parasitic infections. Even resolved infections can leave mast cells primed for months afterward.

A longer, category-by-category list with practical swaps is in our guide to MCAS triggers.

Can COVID-19 or long COVID trigger mast cell activation?

Mast cell activation symptoms are common in long COVID. In a survey study by Weinstock et al. (2021) in the International Journal of Infectious Diseases, 136 people with long COVID reported mast cell activation symptoms after infection that were virtually identical in type and severity to those of 80 untreated MCAS patients, while their pre-COVID symptom scores matched healthy controls. The study relied on self-report, so it shows overlap rather than proof of cause. People exploring this link can read our long COVID condition overview and the long COVID treatment guide.

Diagnosis: Why It's So Difficult and How to Get It Right

Diagnosing MCAS is challenging because standard lab work is often normal between flares, symptoms overlap with dozens of other conditions, and many physicians still aren't familiar with the diagnostic criteria. Both major consensus frameworks, the international proposal by Valent et al. (2012) and the "consensus-2" criteria by Afrin et al. (2021), require all three of the following:

1. Episodic symptoms consistent with mast cell mediator release affecting two or more organ systems
2. Objective evidence of mast cell mediator elevation during a symptomatic episode
3. Response to mast cell-directed therapy (antihistamines, mast cell stabilizers)

How do consensus-1 and consensus-2 criteria differ?

The two frameworks agree on the three pillars but disagree on what counts as proof of mediator release. The 2012 consensus, later turned into a stepwise algorithm by Valent et al. (2019), treats a tryptase rise as the preferred marker. Consensus-2 accepts a broader range of mediator tests, which makes the diagnosis easier to reach and, according to its critics, easier to over-apply.

Diagnostic Testing

Who diagnoses MCAS?

An allergist/immunologist is the usual specialist for an MCAS workup. A hematologist joins when baseline tryptase is high or systemic mastocytosis is suspected, since that question may need a bone marrow biopsy and KIT D816V mutation testing. Gastroenterologists, dermatologists, cardiologists or autonomic specialists (for POTS) and geneticists (for EDS) often contribute pieces of the picture. Our step-by-step MCAS diagnosis guide covers how to prepare for each appointment.

Types of Mast Cell Disorders

Mast cell disorders, also called mast cell diseases, are conditions in which mast cells are too numerous, too reactive, or both. The 2012 consensus by Valent et al. sorts mast cell activation syndromes into three types: primary (also called monoclonal), secondary and idiopathic, alongside systemic mastocytosis. Hereditary alpha-tryptasemia, described by Lyons et al. (2016) at the NIH, is a common genetic trait that can raise baseline tryptase and coexist with any of them.

MCAS vs. Systemic Mastocytosis vs. Histamine Intolerance

These three conditions are frequently confused. Understanding the differences guides treatment and prognosis.

How common is MCAS?

Nobody knows precisely how common MCAS is. The widely quoted figure of about 17% comes from Molderings et al. (2013) in PLoS One, who estimated the prevalence of suspected mast cell activation disease in the German general population from symptom self-report, and found about 46% among first-degree relatives of patients. Specialists who apply the stricter 2012 consensus criteria regard laboratory-confirmed MCAS as much less common, so treat the 17% figure as an upper estimate of symptoms, not of confirmed diagnoses.

Treatment: A Layered Approach

MCAS treatment follows a stepwise, additive approach: you build layers of support until symptoms are adequately controlled. Most patients need multiple interventions working together. The table summarizes the options covered below, with the doses this guide discusses and their US regulatory status, since many are used off label for MCAS.

Tier 1: H1 + H2 Antihistamines (First-Line)

Evidence Grade: Established

H1 plus H2 antihistamines are the foundation of MCAS treatment. Most patients require both H1 and H2 receptor blockers at the same time:

• H1 blockers: Cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra) or hydroxyzine. Many MCAS patients need higher doses than standard allergy dosing, up to 2 to 4 times the over-the-counter dose, under physician supervision.
• H2 blockers: Famotidine (Pepcid) is the preferred H2 blocker, at 20 to 40 mg twice daily. It blocks histamine receptors in the gut and may have a mild mast cell-stabilizing effect. H2 blockade addresses a different set of histamine receptors than H1 and is important for GI symptoms, so it should not be skipped.

Start both antihistamines at standard doses and titrate up as needed. Response to antihistamines is part of the diagnostic criteria: if you improve significantly on H1 plus H2 blockers, that supports the MCAS diagnosis. Our MCAS antihistamine protocol walks through how clinicians typically sequence and adjust them.

Tier 2: Mast Cell Stabilizers

Evidence Grade: Promising

If antihistamines alone aren't sufficient, and for many MCAS patients they won't be, the next layer targets the mast cells themselves, preventing degranulation rather than just blocking what they release:

• Cromolyn sodium (Gastrocrom): Oral mast cell stabilizer that works locally in the gut. Often helpful for GI symptoms such as nausea, cramping, diarrhea and food reactions. Available by prescription. Must be taken 15 to 20 minutes before meals.
• Quercetin: Natural flavonoid with mast cell-stabilizing properties in laboratory studies; human evidence in MCAS is limited. 500 to 1,000 mg twice daily, taken with vitamin C for enhanced absorption. Well tolerated and available over the counter. This is often one of the first supplements MCAS patients notice benefit from.
• Ketotifen: Combined antihistamine and mast cell stabilizer. Not commercially available as an oral drug in the US, so it must be compounded. Used at doses of 0.5 to 2 mg twice daily. Particularly useful for patients who need both antihistamine and stabilizer effects.
• Vitamin C: Natural antihistamine and mast cell stabilizer at doses of 1,000 to 2,000 mg daily. Supports DAO enzyme function for histamine metabolism.
• DAO enzyme supplements: Diamine oxidase taken before meals helps break down dietary histamine before it's absorbed, reducing the histamine load on an already overwhelmed system.

Tier 3: LDN (Low-Dose Naltrexone)

Evidence Grade: Promising

Low-dose naltrexone at 1.5 to 4.5 mg nightly is an emerging, off-label option for MCAS. It modulates the immune system through opioid receptor interactions, may reduce neuroinflammation, and may help restore immune tolerance. Many MCAS patients report improvement in brain fog, fatigue, pain and overall reactivity, though controlled trials in MCAS are lacking. LDN is especially used when MCAS coexists with autoimmune features, chronic pain or POTS. Dosing and titration are covered in our LDN guide.

Tier 4: Advanced Options for Severe/Refractory MCAS

Evidence Grade: Promising

• Omalizumab (Xolair): Anti-IgE monoclonal antibody given by injection. Originally developed for severe asthma, it has shown encouraging results in case reports and small series of severe MCAS that hasn't responded to other treatments. Monthly injections; typically requires prior authorization and specialist management.
• Montelukast (Singulair): Leukotriene receptor blocker. Targets the leukotriene arm of mast cell mediator release and can help respiratory, skin and GI symptoms that don't respond to antihistamines alone. Important caveat: it can cause neuropsychiatric side effects (depression, anxiety, suicidality) in some patients, which is why it carries an FDA boxed warning, as summarized by MedlinePlus montelukast drug information. Monitor closely.
• Compounded combinations: Specialized pharmacies can create custom formulations combining cromolyn, ketotifen and other agents tailored to the individual patient's symptom profile.

Diet and Environmental Management

Medication alone is rarely sufficient. Environmental and dietary management is equally important:

• Low-histamine diet: Reducing dietary histamine lowers the total mediator burden on your system. See our histamine intolerance guide for food lists and meal planning.
• Trigger diary: Track symptoms alongside foods, environments, activities, stress levels and menstrual cycle. Patterns often emerge after 2 to 4 weeks of consistent tracking.
• Mold avoidance: If mold is a trigger (and it is for many MCAS patients), environmental remediation is essential: HEPA air filtration, mold inspection and, potentially, moving out of a contaminated space. See our mold illness guide.
• Stress management: Stress is one of the most potent mast cell triggers. Vagus nerve exercises and nervous system regulation techniques can meaningfully reduce mast cell reactivity.
• Fragrance-free products: Switch to unscented personal care, laundry and cleaning products.

The MCAS-POTS-EDS Triad

This connection is so important it deserves its own section. MCAS frequently coexists with POTS (Postural Orthostatic Tachycardia Syndrome) and EDS (Ehlers-Danlos Syndrome). The triad is so common that finding one condition should automatically prompt evaluation for the other two.

The proposed mechanism: EDS involves defective collagen and connective tissue, the tissue where mast cells reside. Abnormal connective tissue may create a dysfunctional environment that makes mast cells more prone to inappropriate activation (MCAS). The chemical mediators released by activated mast cells, particularly histamine and prostaglandins, affect blood vessel tone and autonomic nervous system function, contributing to the tachycardia, blood pressure instability and orthostatic intolerance seen in POTS. Seneviratne et al. (2017) reviewed mast cell disorders in Ehlers-Danlos syndrome, and a genetic thread runs through the cluster too: the hereditary alpha-tryptasemia families described by Lyons et al. (2016) in Nature Genetics often reported flushing, dysautonomia and joint hypermobility together.

In practical terms: if you have hypermobility (EDS), a racing heart when you stand up (POTS), and mysterious multi-system symptoms (MCAS), you may have all three, and treating each one helps the others. The POTS treatment guide and the broader dysautonomia treatment overview cover the autonomic side, and our deep dive on the MCAS, POTS and EDS triad explains how clinicians sequence care across all three.

How to Find an MCAS-Literate Provider

An MCAS-literate provider knows both consensus criteria, orders mediator tests timed to flares, builds treatment in layers, and screens for POTS and EDS. Allergist/immunologists lead most workups; functional and integrative medicine physicians often manage the long-term trigger, diet and environment work, ideally in coordination with conventional specialists.

Regenerated.com does not list a separate clinic category for MCAS, so the most practical route is to look for clinicians who name mast cell activation in their profile while browsing the directory. Listing order on Regenerated.com is not paid ranking, Featured slots are labeled and capped, Verified means a clinic completed credential checks rather than paid for placement, and the directory is free for patients. Inclusion is not an endorsement, so ask each clinic how it confirms the diagnosis. Our guide to Featured, Verified and organic listings explains each label in detail.

Frequently Asked Questions

What is MCAS?

MCAS, or mast cell activation syndrome, is an immune disorder in which normal-count mast cells release histamine, tryptase, prostaglandins and other mediators too easily. It causes episodic symptoms in two or more organ systems, such as flushing, hives, gut cramping, wheezing, brain fog and a fast heart rate. Diagnosis requires typical symptoms, a measured mediator rise during a flare, and improvement on mast cell-directed treatment, according to the Valent et al. (2012) consensus.

Is MCAS an autoimmune disease?

MCAS is not an autoimmune disease in the classic sense. It is immune dysregulation: your mast cells are overreactive, but they are not attacking your own tissues the way autoimmune antibodies do. MCAS can coexist with autoimmune conditions such as Hashimoto's thyroiditis, and some researchers believe chronic mast cell activation may contribute to autoimmune processes by disrupting immune tolerance and promoting chronic inflammation, although that link is still being studied.

Can MCAS go into remission?

MCAS is a chronic condition that is managed over time, and many patients reach good symptom control with the right mix of medication, diet and trigger avoidance. Some experience long periods of remission, especially after addressing contributors like SIBO, mold exposure, chronic infections or hormonal imbalances. The goal is to lower the total burden on mast cells until they settle at a less reactive baseline.

How is MCAS diagnosed if labs are normal?

Normal labs between flares do not rule out MCAS, because the criteria require mediator testing during a symptomatic episode. If your tryptase was normal on a routine draw, ask your provider about 24-hour urine N-methylhistamine and prostaglandin D2 metabolites collected while symptoms are active, plus a tryptase drawn within 1 to 4 hours of a flare. A documented response to H1 plus H2 antihistamines or cromolyn fulfills the third diagnostic criterion.

What is a mast cell flare?

A mast cell flare is an episode of increased mast cell activation with worsening symptoms in any combination of organ systems. Flares last hours to weeks and may follow an identifiable trigger, such as food, stress, heat or a hormonal change, or appear without an obvious cause. Management usually means stepping up baseline medication with your clinician, strict trigger avoidance, rest and hydration, and epinephrine if signs of anaphylaxis appear.

What is the connection between MCAS and POTS?

Histamine and prostaglandins released by activated mast cells widen blood vessels, which drops blood pressure and triggers a compensatory fast heart rate. That is why many POTS patients notice their heart rate and orthostatic symptoms worsen during MCAS flares and ease when mast cells are better controlled. Clinic-based estimates suggest that up to 50% of POTS patients may have MCAS as a contributing factor, though population data are limited.

Is MCAS genetic?

MCAS appears to have a genetic predisposition. Molderings et al. (2013) found suspected mast cell activation disease in about 46% of first-degree relatives of patients, and researchers have identified variants in genes involved in mast cell function, including KIT and related pathways. The typical pattern is a genetic predisposition plus an environmental trigger, such as infection, mold, physical trauma, stress or a hormonal change, which is why MCAS often emerges after a specific event.

What should I eat with MCAS?

Start with a low-histamine diet: avoid aged cheeses, fermented foods, processed meats such as salami, alcohol, vinegar, leftovers and canned fish, and eat fresh food prepared and eaten quickly. Many MCAS patients also react to high-oxalate foods, lectins or individual triggers unrelated to histamine. A systematic elimination and reintroduction plan guided by a symptom diary identifies personal triggers most reliably. See our histamine intolerance guide for thorough food lists.

How do I find a doctor who understands MCAS?

Look for allergist/immunologists, functional medicine physicians or integrative medicine specialists who name MCAS in their practice focus. A knowledgeable provider knows the consensus diagnostic criteria, uses a layered treatment approach rather than a single antihistamine, considers the MCAS, POTS and EDS connection, has experience with mast cell stabilizers such as cromolyn and ketotifen, and is willing to test during flares instead of dismissing normal baseline labs.

Related Topics

• MCAS Symptoms: Detailed organ-by-organ symptom breakdown and tracking tools
• POTS (Postural Orthostatic Tachycardia Syndrome): Diagnosis, treatment, and the MCAS connection
• Ehlers-Danlos Syndrome: Hypermobility, diagnosis, and how EDS drives MCAS and POTS
• Histamine Intolerance: Diet strategies, DAO enzymes, and reducing histamine load
• Low-Dose Naltrexone (LDN): Immune modulation for MCAS, chronic pain, and autoimmunity
• Brain Fog: Neuroinflammation, histamine, and cognitive dysfunction
• Mold Illness / CIRS: One of the most potent MCAS triggers and how to address it
• SIBO: Gut inflammation as a driver of mast cell activation

Sources

1. Afrin LB, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis. 2021;8(2):137-152.
2. Molderings GJ, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10.
3. Theoharides TC, et al. Mast cells, brain inflammation and autism. Eur J Pharmacol. 2016;778:96-102.
4. Seneviratne SL, et al. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C. 2017;175(1):226-236.
5. Valent P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.
6. Weinstock LB, et al. Mast cell activation syndrome and the link with EDS and POTS. Clin Rev Allergy Immunol. 2021;60(3):452-460.
7. Afrin LB. Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media, 2016.
8. Valent P, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-225.
9. Lyons JJ, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-1569.
10. Molderings GJ, et al. Familial occurrence of systemic mast cell activation disease. PLoS One. 2013;8(9):e76241.
11. Weinstock LB, et al. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021;112:217-226.